The Ruhr University Bochum team's immuno-infrared sensor represents a methodological advance in isolating secondary structure changes in amyloid-beta and alpha-synuclein directly from plasma, yet the Journal of Physical Chemistry B paper functions primarily as a proof-of-concept technical report rather than a definitive clinical validation study. No large-scale RCT data or population-level prevalence figures are presented, leaving open questions about false-positive rates in asymptomatic cohorts and long-term predictive value. This approach could intersect with the recent FDA approvals of lecanemab and donanemab by enabling treatment initiation years earlier than current PET or CSF thresholds allow, an angle the original coverage underplays. Complementary work from Palmqvist et al. (Nature Medicine, 2023) on plasma p-tau217 demonstrates high accuracy in memory-clinic settings (n>1,000) but highlights the same scalability challenge this quantum-cascade-laser platform aims to solve. Gerwert's BetaSENSE spin-off introduces a clear commercial conflict of interest that warrants independent replication. Population screening ethics, including psychological impact of preclinical diagnoses without proven disease-modifying benefit, remain unaddressed gaps.